Effect of rose hip on coronary slow flow

The effect of rose hip alcoholic extract on transthoracic Doppler echocardiography parameters in patients with coronary slow flow

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120520009801N8

Enrollment

Registered

2022-07-30

Start date

2022-09-23

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery slow flow syndrome. Other forms of angina pectoris

Interventions

Intervention 1: Intervention group: tablets containing 250 mg of hydroalcoholic extract of rose hip prepared in the pharmacognosy and pharmaceutical laboratory of Mashhad Faculty of Pharmacy, 4 tablet

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosis of slow flow review based on angiography results CTFC (corrected TIMI frame count) > 27 Obtaining the consent of the patient or the patient's companion

Exclusion criteria

Exclusion criteria: Aneurysm in the coronary arteries Patients with hyperhomocysteinemia Patients with myocarditis Patients with pericarditis Patients with cardiomyopathy The presence of ectasia in epicardial coronary vessels Not having a suitable view for electrocardiography Pregnancy or lactation Kidney or liver failure

Design outcomes

Primary

Measure	Time frame
PDV (peak diastolic velocity). Timepoint: at baseline and two months after intervention. Method of measurement: Echocardiography.;MDV (mean diastolic velocity). Timepoint: at baseline and two months after intervention. Method of measurement: Echocardiography.;PDP (peak diastolic pressure). Timepoint: at baseline and two months after intervention. Method of measurement: Echocardiography.;MDP (mean diastolic pressure). Timepoint: at baseline and two months after intervention. Method of measurement: Echocardiography.;Dvti(diastolic time velocity). Timepoint: at baseline and two months after intervention. Method of measurement: Echocardiography.;Dint (diastolic flow interval). Timepoint: at baseline and two months after intervention. Method of measurement: Echocardiography.;VTI (time velocity integral). Timepoint: at baseline and two months after intervention. Method of measurement: Echocardiography.;LVEF (left ventricular ejection fraction). Timepoint: at baseline and two months after intervention. Method of measurement: Echocardiography.	—

Measure

Time frame

PDV (peak diastolic velocity). Timepoint: at baseline and two months after intervention. Method of measurement: Echocardiography.;MDV (mean diastolic velocity). Timepoint: at baseline and two months after intervention. Method of measurement: Echocardiography.;PDP (peak diastolic pressure). Timepoint: at baseline and two months after intervention. Method of measurement: Echocardiography.;MDP (mean diastolic pressure). Timepoint: at baseline and two months after intervention. Method of measurement: Echocardiography.;Dvti(diastolic time velocity). Timepoint: at baseline and two months after intervention. Method of measurement: Echocardiography.;Dint (diastolic flow interval). Timepoint: at baseline and two months after intervention. Method of measurement: Echocardiography.;VTI (time velocity integral). Timepoint: at baseline and two months after intervention. Method of measurement: Echocardiography.;LVEF (left ventricular ejection fraction). Timepoint: at baseline and two months after intervention. Method of measurement: Echocardiography.

—

Secondary

Measure	Time frame
Adverse reactions of rose hip tablet. Timepoint: Two months after intervention. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Hooshang Mohammadpour

Mashhad University of Medical Sciences

mohamadpoorah@mums.ac.ir+98 51 1882 3255

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026